128P - Is Fotemustine a good option after irinotecan-bevacizumab in high-grade glioma? (128P)

Date 18 November 2017
Event ESMO Asia 2017 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Central Nervous System Malignancies
Presenter Patricia Ramirez Daffós
Citation Annals of Oncology (2017) 28 (suppl_10): x35-x38. 10.1093/annonc/mdx657
Authors P. Ramirez Daffós, M.J. Martinez Bautista, G. Blanco Sanchez(, S. Estalella, J.M. Baena Cañada
  • Medical Oncology, Puerta del Mar, 11006 - cadiz/ES



Recurrent high-grade glioma (GAG), don't usually benefit from a second surgery or reirradiation. With the addition of bevacizumab or fotemustine (FTM), the median OS is 9.2 and 8 months, respectively. There is no currently clinical trial showing a 3rd line treatment benefit in recurrent GAG. The aim of this study is to describe the clinical experience in our hospital with FTM in 3rd line.


An observational, retrospective study was conducted. All patients had progressed to temozolomide and irinotecan+bevacizumab and had received at least one cycle of fotemustine (FTM) from 2010 to the present. The schedule was: induction doses with 80 mg/m2 intravenously on days 1–15–30–45–60 and maintenance with 80 mg/m2 every 3 weeks.


7 patients were included, 5 women, median age 41 years, 42% (n = 3) were anaplastic astrocytomas and 58% (n = 4) multiform glioblastoma, 100% of the patients had PS 0–1. To date, 6 of the 7 patients had progressed, with a median PFS of 1 month. The 3- month survival rate was 71.42%, and the median OS (5/7 deceased patients) was 3.3 months. No adverse events of grade ≥3 were reported.


Fotemustine in third line treatment of GAG shows moderate effectiveness but is a well tolerated treatment, so it could be considered in the third line in patients with GAG with good functional status.

Legal entity responsible for the study

Patricia Ramirez

Funding: None

Disclosure: All authors have declared no conflicts of interest.

Clinical trial identification